By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today reported a 35 percent increase in third-quarter revenues but fell short of analyst EPS estimates by a penny.

For the three months ended Sept. 30, the firm said it had $418.4 million in revenues, up from $310.2 million a year ago and ahead of Wall Street expectations of $393.2 million. Organically revenues were up 11 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.